Deals
Chinese Cancer Screening Firm to Pick Goldman, UBS for IPO
- New Horizon Health is seeking about $300 million in H.K. IPO
- The Chinese startup is backed by Qiming, Legend Capital
This article is for subscribers only.
New Horizon Health Ltd., a Chinese maker of home test kits for colon cancer, has picked Goldman Sachs Group Inc. and UBS Group AG to arrange its planned initial public offering in Hong Kong, according to people familiar with the matter.
The seven-year-old company is considering raising about $300 million from the share sale, said the people, requesting not to be named because the matter is private. The startup, which counts Qiming Venture Partners and Duke Management Co. among its investors, aims to kick off the share sale as soon as the third quarter, one of the people said.